McKesson Corporation
MCK
$938.84
+0.92%
McKesson Corporation is one of the three dominant U.S. pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty drugs to retail pharmacy chains, independent pharmacies, mail-order operators, hospital networks, and healthcare providers, while also operating medical-surgical distribution and pharmacy technology businesses and a wholesale operation in Canada. Alongside Cencora and Cardinal Health, McKesson controls over 90% of the U.S. pharmaceutical wholesale market, giving it a distinct oligopolistic position characterized by immense revenue scale, razor-thin margins, and high barriers to entry built on distribution density and manufacturer relationships. The current investor narrative centers on the company's ability to convert low-single-digit revenue growth into double-digit adjusted earnings growth through generic drug sourcing gains, specialty oncology expansion, and aggressive share repurchases, reinforced by a recent fiscal Q1 2027 beat and raised guidance that prompted Zacks to call the stock a solid hold. Attention is also focused on capital deployment after McKesson and CD&R agreed to acquire Option Care Health for $32.05 per share at a 37% premium, a deal that signals management's appetite for bolt-on expansion into home infusion and alternate-site care. At the same time, the stock's premium multiple and the persistent debate over drug pricing reform, generic deflation, and customer concentration keep valuation risk at the center of the bull-bear debate.…
MCK
McKesson Corporation
$938.84
Related headlines
Investment Opinion: Should I buy MCK Today?
McKesson earns a Hold rating with a balanced thesis: the company's oligopolistic market position, double-digit EPS growth, and strong free cash flow support a premium valuation, but razor-thin margins and regulatory risks limit upside. The analyst consensus is 'buy' with an average target of $980.67, implying 4.5% upside, but the Zacks Rank #3 suggests limited near-term catalysts. The core reasoning is that McKesson is a high-quality defensive holding, but its current valuation already reflects much of the positive outlook.
Supporting evidence includes a forward PE of 18.6x, which is reasonable relative to expected EPS growth, a PEG ratio of 0.46 indicating undervaluation relative to growth, and a dividend yield of 0.36% with a low payout ratio of 8%, providing room for future increases. Revenue grew 7.72% year-over-year in Q1 FY2027, and free cash flow of $6.185 billion supports continued buybacks. However, gross margin of 3.61% and operating margin of 1.60% are thin, and the negative debt-to-equity ratio of -3.97 reflects financial leverage. The implied upside to the average analyst target is only 4.5%, suggesting the stock is fairly valued.
Key risks that could invalidate the thesis include regulatory changes to drug pricing, accelerated generic deflation, and customer concentration. The rating would upgrade to Buy if the stock pulls back to the $850–$880 range (PE below 17x) or if revenue growth accelerates above 10% with margin expansion. It would downgrade to Sell if operating margins fall below 1.5% or if a major customer is lost. Relative to its history and peers, McKesson appears fairly valued, with the market pricing in steady execution but not significant multiple expansion.
Sign up to view all
MCK 12-Month Price Forecast
McKesson presents a balanced risk-reward profile, with a strong oligopolistic position and consistent cash flows offset by thin margins and regulatory risks. The stock is fairly valued at 18.6x forward earnings, with limited upside to the analyst average target. The base case (55% probability) suggests a target range of $950–$1,000, reflecting steady execution. I would upgrade to bullish if the stock pulls back to the $850–$880 range or if margin expansion exceeds expectations; I would downgrade to bearish if operating margins fall below 1.5% or if regulatory headwinds intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on McKesson Corporation's 12-month outlook, with a consensus price target around $980.67 and implied upside of +4.5% versus the current price.
Average Target
$980.67
0 analysts
Implied Upside
+4.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$845 - $1070
Analyst target range
Bulls vs Bears: MCK Investment Factors
The bull case for McKesson rests on its oligopolistic market position, consistent double-digit EPS growth, strong free cash flow, and defensive low-beta profile, supported by a 'buy' analyst consensus and 4.5% upside to the average target. However, the bear case highlights razor-thin margins, premium valuation, customer concentration, regulatory risks, and a leveraged balance sheet. Currently, the bull evidence appears stronger given the company's track record of earnings beats, raised guidance, and strategic acquisitions like Option Care Health, but the most critical tension is whether McKesson can sustain its premium multiple if generic deflation accelerates or drug pricing reforms materialize. The resolution of this tension will likely determine whether the stock continues its outperformance or faces a significant correction.
Bullish
- Oligopoly with high barriers: McKesson, Cencora, and Cardinal Health control over 90% of the U.S. pharmaceutical wholesale market, creating a durable oligopoly with immense distribution density and manufacturer relationships that are extremely difficult to replicate. This structural advantage supports consistent cash generation and pricing power.
- Double-digit EPS growth expected: Analysts estimate FY2027 EPS of $80.34, up from $5.17 in Q1 FY2027 alone, implying strong double-digit growth driven by generic sourcing gains, specialty oncology expansion, and share repurchases. The forward PE of 18.6x is below the trailing PE of 22.4x, reflecting expected earnings acceleration.
- Strong free cash flow and buybacks: McKesson generated $6.185 billion in trailing free cash flow, enabling aggressive share repurchases that reduce shares outstanding from 125.5 million in Q1 FY2026 to 119.2 million in Q1 FY2027. This capital return strategy amplifies EPS growth and supports the stock's premium valuation.
- Analyst consensus buy with upside: 12 analysts rate MCK a 'buy' with an average target price of $980.67, implying 4.5% upside from the current $938.84. The high target of $1,070 suggests 14% potential upside, reflecting confidence in the company's earnings trajectory and strategic initiatives.
Bearish
- Razor-thin margins limit flexibility: Gross margin is only 3.61% and operating margin 1.60%, leaving little room for error. Any cost inflation, pricing pressure, or generic deflation could quickly erode profitability, as seen in Q1 FY2027 when net income fell to $614 million from $784 million in the prior-year quarter despite revenue growth.
- Premium valuation vulnerable to compression: The trailing PE of 22.4x and forward PE of 18.6x are rich for a low-margin distributor, especially with a PEG ratio of 0.46 that may not fully capture risks. If earnings growth decelerates, the multiple could contract sharply, as evidenced by the 27.17% max drawdown over the past 180 days.
- Customer concentration risk: McKesson relies heavily on a few large customers, including retail pharmacy chains and hospital networks. Loss of a major contract or consolidation among customers could significantly impact revenue and bargaining power, as hinted by the competitive pressure from Cencora's raised EPS outlook.
- Regulatory and drug pricing overhang: Ongoing debates over drug pricing reform, generic deflation, and potential changes to reimbursement models pose persistent risks. Any adverse legislation could compress margins further, given the already thin 1.6% operating margin, and negatively impact earnings.
MCK Technical Analysis
Beta
0.30
0.30x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$724-$999
Price range past year
Annual Return
+23.9%
Cumulative gain past year
| Period | MCK Return | S&P 500 |
|---|---|---|
| 1m | +5.3% | +1.9% |
| 3m | +16.5% | +3.9% |
| 6m | +8.5% | +12.1% |
| 1y | +23.9% | +19.2% |
| ytd | +14.0% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MCK Fundamental Analysis
Quarterly Revenue
$105.4B
2026-06
Revenue YoY Growth
+7.7%
YoY Comparison
Gross Margin
3.5%
Latest Quarter
Free Cash Flow
$6.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MCK Overvalued?
PE
22.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for McKesson are substantial given its razor-thin margins and leveraged balance sheet. Gross margin stands at just 3.61%, and operating margin at 1.60%, leaving minimal buffer against cost increases or pricing pressure. The current ratio of 0.85 suggests potential liquidity tightness, while the negative debt-to-equity ratio of -3.97 reflects a capital structure reliant on debt and negative equity, which could become problematic if interest rates rise or credit conditions tighten. Additionally, customer concentration among large pharmacy chains and hospital networks means the loss of a key contract could disproportionately impact revenue and profitability.
Market and competitive risks include valuation compression and sector rotation. McKesson trades at a trailing PE of 22.4x and forward PE of 18.6x, a premium to many healthcare distributors, which leaves it vulnerable if growth slows. The beta of 0.298 indicates low correlation with the broader market, but this defensive characteristic may lead to underperformance in bull markets. Competitive pressures are evident as rivals like Cencora raise EPS outlooks on specialty strength, and Cardinal Health's generics business remains a profit engine, potentially eroding McKesson's market share. Regulatory risks, including drug pricing reform and generic deflation, could further compress margins.
The worst-case scenario involves a combination of regulatory crackdown on drug pricing, accelerated generic deflation, and loss of a major customer, leading to margin compression and earnings misses. This could trigger a valuation reset, pushing the stock toward its 52-week low of $723.68, representing a 22.9% decline from the current price of $938.84. Analyst low target of $845 implies a 10% downside, but in a severe scenario, the stock could test the 52-week low, resulting in a loss of approximately 23% for investors. The max drawdown of 27.17% over the past 180 days underscores the potential for significant declines in adverse conditions.
FAQ
The most severe risk is regulatory intervention in drug pricing, which could compress McKesson's already thin 1.6% operating margin. Financial risks include a current ratio of 0.85 and negative debt-to-equity of -3.97, indicating leverage and potential liquidity constraints. Competitive risks arise from rivals like Cencora and Cardinal Health strengthening their specialty and generics businesses, potentially eroding market share. Company-specific risks include customer concentration, as loss of a major pharmacy chain or hospital network could significantly impact revenue. Additionally, the stock's premium valuation leaves it vulnerable to multiple compression if growth slows.
The 12-month forecast for McKesson includes a base case (55% probability) with a target range of $950–$1,000, assuming steady revenue growth of 7-8% and stable margins. The bull case (25% probability) targets $1,000–$1,070, driven by successful acquisition integration and margin expansion. The bear case (20% probability) targets $723–$845, reflecting regulatory headwinds or margin compression. The most likely scenario is the base case, hinging on McKesson meeting EPS estimates of $80.34 and maintaining its current valuation multiple. Key assumptions include no adverse drug pricing legislation and continued share repurchases.
McKesson appears fairly valued, trading at a trailing PE of 22.4x and a forward PE of 18.6x, which is in line with its historical average and reasonable for a low-margin distributor. The PEG ratio of 0.46 suggests undervaluation relative to expected earnings growth, but the price-to-sales ratio of 0.27 reflects the company's high revenue base and thin margins. Compared to peers like Cencora and Cardinal Health, McKesson's valuation is slightly premium, justified by its scale and consistent execution. The market is pricing in steady growth and no major regulatory disruptions, leaving limited room for multiple expansion.
McKesson is a good buy for conservative investors seeking a defensive healthcare holding with a reliable dividend and share buyback program. The stock trades at $938.84, with a forward PE of 18.6x and a PEG ratio of 0.46, suggesting reasonable valuation relative to growth. Analysts have a 'buy' consensus with an average target of $980.67, implying 4.5% upside, but the Zacks Rank #3 indicates limited near-term catalysts. The biggest downside risk is regulatory pressure on drug pricing, which could compress margins. Overall, it is a solid core holding for long-term investors, but those seeking high growth may find better opportunities elsewhere.
McKesson is best suited for long-term investment due to its low beta of 0.298, stable cash flows, and consistent capital returns, making it a defensive holding for conservative portfolios. Short-term trading is less attractive given the limited analyst upside of 4.5% and the stock's low volatility, which reduces the potential for quick gains. The company's dividend yield of 0.36% and payout ratio of 8% indicate a focus on buybacks over income, appealing to total-return investors. A minimum holding period of 2-3 years is recommended to ride out regulatory uncertainties and benefit from earnings growth and buybacks. Earnings visibility is moderate, with quarterly fluctuations but a stable long-term trajectory.